Home Overview Press Room Blog Publications For Students about us
Search

Synthetic Biology : Displaying 37-46 of 265


The Possibility Of A Three-Parent Baby[cites CGS' Marcy Darnovsky]by Indira LakshamananThe Diane Rehm ShowFebruary 25th, 2016A discussion about the science, ethics, and politics of a controversial technique that is a form of inheritable genetic modification.
What’s the difference between genetic engineering and eugenics?by Robert GebelhoffThe Washington PostFebruary 22nd, 2016Where we draw the line between "negative eugenics" and "positive genetic intervention" is a political question.
Who's Looking to Profit from Human Germline Changes?by Pete ShanksBiopolitical TimesJanuary 28th, 2016Billionaire Randal Kirk has assembled the components to commercialize heritable human genetic modification.
Why Is Editas Going Public? by Pete ShanksBiopolitical TimesJanuary 14th, 2016Editas, the gene-editing company founded by several of the scientists who developed CRISPR technology, announced on January 4th that it had filed preliminary paperwork for a public offering of stock.
Synthetic Biology's Defense Dollars: Signals and Perceptions by Dr. Filippa LentzosPLOS BlogsDecember 24th, 2015DARPA aims to develop radically new, game-changing technologies for national security and to create technological surprises for its enemies.
Livetweeting #GeneEditSummit: Democratized Debate or Segregated Conversations?by Elliot Hosman, Biopolitical TimesDecember 10th, 2015Though #GeneEditSummit was trending on Twitter, inclusive public debate must be more robust than the livetweeting of insular stakeholder meetings.
Extreme Genetic Engineering and the Human FutureReclaiming Emerging Biotechnologies for the Common GoodThe Center for Genetics and Society and Friends of the Earth examine the human applications of synthetic biology. This 50-page report challenges claims that this new set of genetic engineering techniques should be seen as "the future of manufacturing, engineering and medicine."
Gene Therapy: Comeback? Cost-Prohibitive?by Elliot Hosman, Biopolitical TimesNovember 19th, 2015Recent CRISPR news sometimes confuses germline modification - which should be put off limits - and gene therapy, which presents its own set of social and ethical risks to resolve before rushing to market.
[UK] Baby girl is first in the world to be treated with 'designer immune cells'by Ian SampleThe GuardianNovember 5th, 2015Genetically engineered cells were used to successfully treat an aggressive form of childhood leukaemia, though the experimental treatment had only been tested on mice.
GMO Propaganda and the Sociology of Scienceby Kristine MattisCounterpunchOctober 5th, 2015The false association between anti-GMO and anti-science sentiment obscures the lack of scientific consensus about the health and environmental effects of genetically modified crops.
Displaying 37-46 of 265  
< Prev  Next >> 
« First Page Last Page » 
« Show Complete List » 


ESPAÑOL | PORTUGUÊS | Русский

home | overview | blog | publications| about us | donate | newsletter | press room | privacy policy

CGS • 1122 University Ave, Suite 100, Berkeley, CA 94702 • • (p) 1.510.665.7760 • (F) 1.510.665.8760